Ascletis Pharma raises HK$468m for obesity drug research

Ascletis Pharma Inc. completed a placing of 52.4 million shares at HK$16.45 per share, followed by a top-up subscription of 28.8 million new shares at the same price, raising net proceeds of HK$467.69 million.

Approximately 90% of proceeds will fund research and development of drug candidates for obesity, with the remaining 10% for working capital and general corporate purposes.